Real-world safety profile of finerenone in patients with type 2 diabetes and chronic kidney disease: a multi-database pharmacovigilance analysis of the FAERS and JADER systems.
Real-world safety data confirms finerenone protects kidney and heart health in diabetic patients with minimal unexpected adverse effects.
Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has been shown to lower the risk of renal and cardiovascular events in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). A total of 1,545 (FAERS) and 210 (JADER) reports with finerenone as the primary suspect were identified.
What the study was
- Study design
- Clinical Trial
- Population
- Patients with (see abstract)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Frontiers in clinical diabetes and healthcare
Why it surfaced
Design: Clinical Trial; Topics: Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; Species: human. Score=6/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.